Mayank A. Nanavaty, MBBS, DO, FRCOphth, FWCRS, PhD

Two cases highlight the diagnostic challenges of Demodex blepharitis and underscore the unmet need for approved targeted therapies in the United Kingdom.

Prof. Nanavaty reviews UK treatment practices, emphasizing that the lack of Demodex-specific therapies leads to mismanagement, increased healthcare burden, and complications, while highlighting the need for better diagnosis and targeted treatment.

Prof. Nanavaty outlines Demodex blepharitis, highlights colorette counts as a measure of severity, and emphasizes that despite its high prevalence in patients, it is frequently overlooked and should be routinely assessed during eye exams.